Pregnancy & Fertility Testing Products Market is Segmented By Devices(Digital Device and Line-Indicator Devices), By Distribution Channel(Pharmacies, Gynecology & Fertility Clinics, Online Sales and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Pregnancy & fertility testing products market is high estimated to reach at a CAGR 8.6% during the forecast period (2022-2029).
A pregnancy test determines whether a woman is pregnant or not. The two basic approaches are testing for human pregnancy hormones in blood or urine and ultrasonography. At the same time, fertility testing is the process of assessing fertility in general and determining the "fertile window" in the menstrual cycle.
Pregnancy & Fertility Testing Products Market Dynamics
The factors driving the market growth are the latest technological developments in pregnancy & fertility testing
An increase in technological advancements in pregnancy & fertility testing is expected to drive the market in the forecast period
Women's health innovations are fast reshaping the health care landscape. The FDA has approved the first-ever digital contraception, Natural Cycle's fertility tracking software, which pairs with a basal thermometer to allow women to prepare for or avoid pregnancy through temperature logging. Antibodies are used in pregnancy tests to detect human chorionic gonadotropin (hCG). It is an excellent pregnancy indicator since it rises swiftly and reliably in early pregnancy and may be found in urine. The most advanced home pregnancy test available today assesses the level of hCG detected in urine and claims to offer women trustworthy findings within a few weeks of pregnancy. In Germany, over 15 different home pregnancy tests are now available for purchase over the counter. Modern pregnancy tests employ a form of technology known as a lateral flow device (LFD). A lateral flow device comprises many distinct types of paper that have pores (small holes) of varying sizes.
On August 20, 2020, ACON Laboratories, Inc. obtained FDA Over The Counter (OTC) clearance for its Distinct® Early Detection Pregnancy test. The test detects human chorionic gonadotropin (hCG) in urine qualitatively and can help users predict pregnancy as early as six days before the missed period.
On July 2, 2018, Merck launched QBOX IVF and the new Geri® Assess 2.0 as part of its new technologies for improved efficiency in fertility labs.
Unawareness of these products and their less accuracy is expected to hamper the global pregnancy & fertility testing products market
Early detection of unwanted pregnancy is hampered in low-income settings by a lack of understanding and awareness of fertility and pregnancy signs and symptoms, exacerbated by a mistrust of commercially accessible pregnancy tests. Improving community awareness of pregnancy risk and early warning signals, as well as making free tests easily available, may assist women experiencing unexpected pregnancies in confirming their pregnancy status as soon as possible. Many women are not aware of the testing kits available in the market and their usage.
Pregnancy & Fertility Testing Products Market Segment Analysis
By devices, digital devices held the largest market share in the pregnancy & fertility testing products market
Digital tests indicate "pregnant" or "not pregnant." Even a faint line could indicate a favorable outcome. As a result, digital tests remove the uncertainty from interpreting a pregnancy test. A small computer is included in digital pregnancy tests, which scans the strip and displays the findings on a small LCD screen.
For example, the FIRST RESPONSETM Gold Digital Pregnancy Test is an at-home urine pregnancy test, which includes First to DetectTM Technology, sensitive enough to detect early levels of pregnancy hormones and can provide findings up to 6 days earlier than a missed period. The Clearblue Digital Pregnancy Test with Smart Countdown is the only test that tells when and whether the test is working. This digital pregnancy test has a unique progress indicator that counts down, and the outcome is digitally shown in words. The extra-wide tip makes it simple to use, and the innovative FloodguardTM Technology on the inside prevents excess urine from entering the device and producing test mistakes.
On 28th May 2019, The FDA approved the VeriClear Digital Early Result Pregnancy Test (True Diagnostics), which can detect a pregnancy as early as 6 days before a missed period.
On September 7, 2018, Mira launched TechCrunch Disrupt SF, a revolutionary device designed to assist women who are having difficulty conceiving.
Pregnancy & Fertility Testing Products Market
|
Metrics |
Details |
|
Market CAGR |
8.6% |
|
Segments Covered |
By Devices, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Pregnancy & Fertility Testing Products Market Geographical Analysis
North America region accounted for the largest market share in the global pregnancy & fertility testing products market
With the increasing prevalence of infertility incidence and product launches, this region is expected to dominate the market
It is estimated that over 12% of women in the United States have difficulty getting pregnant. Infertility is predicted to become increasingly common as people wait longer to start having children. After a year of trying, approximately 6% of married women aged 15 to 44 in the United States cannot conceive (infertility). In addition, approximately 12% of women aged 15 to 44 in the United States have trouble getting pregnant or bringing a pregnancy to term (impaired fecundity).
According to statistics, 92 million women in the U.S. used home pregnancy tests in 2020.
On December 13th, 2017, a start-up in the United States, Lia launched a flushable pregnancy test made of sustainable, biodegradable materials, which they claim is the first of its type.
Pregnancy & Fertility Testing Products Market Competitive Landscape
The global pregnancy & fertility testing products market is highly competitive with the increasing demand for home-testing kits and technological advancements in recent product launches.
Some of the major key players in the global pregnancy & fertility testing products market are Quidel Corporation, Alere Inc, Church & Dwight Co., Inc., bioMrieux SA, Geratherm Medical AG, Abbott Laboratories, Procter & Gamble Co., Biosynex and Swiss Precision Diagnostics GmbH
Procter & Gamble Co.
Overview: Procter & Gamble Co., known as P&G, is an American global consumer goods corporation headquartered in downtown Cincinnati, Ohio. P&G is the world's largest consumer packaged products firm, with about $84 billion in sales and more than $10 billion in net earnings.
Product Portfolio: The company’s product is Clearblue ® Connected Ovulation Test System. It is the most recent advancement in ovulation testing, combining the accuracy of the Clearblue® Ovulation Test with the convenience of an app.
Key Development: In October 2017, Swiss Precision Diagnostics, a subsidiary of Procter & Gamble that sells the Clearblue fertility test, unveiled a new version of their testing instrument that includes Bluetooth connectivity and a digital app.
Frequently Asked Questions
What is the Projected CAGR value of the Pregnancy & Fertility Testing Products Market?
Pregnancy & Fertility Testing Products Market is expected to grow at a CAGR of 8.6% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Pregnancy & Fertility Testing Products Market during 2022-2029
Which is the fastest growing region in the Pregnancy & Fertility Testing Products Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period